1. Scrip

Key Kyowa Kirin, Dainippon Sumitomo drugs opened up to generics in Japan

 
• By Ian Haydock

The latest reimbursement price listing of generic drugs in Japan includes nine active ingredients opened up to such competition for the first time, including Kyowa Hakko Kirin's and Dainippon Sumitomo Pharma's (DSP) number two products and others from AstraZeneca and Astellas.

The latest reimbursement price listing of generic drugs in Japan includes nine active ingredients opened up to such competition for the first time, including Kyowa Hakko Kirin's and Dainippon Sumitomo Pharma's (DSP) number two products and others from AstraZeneca and Astellas.

In all, 595 preparations from 63 firms were included in the reimbursement tariff (which allows launch) on 14 December, in one of two generic price listings annually in the country,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.